VIZIENT, INC. for VIZIENT INC

Tariff (miscellaneous tariff bills) TAR

Tariffs - Raised concerns about the impact of proposed tariffs on the cost of prescription drugs and medical supplies.

Contacted: Drug Enforcement Administration (DEA); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Taxation/Internal Revenue Code TAX

Hospital Tax Exemption and Community Benefit - Monitored congressional activities for potential changes to hospital community benefit requirements to maintain tax exemption. Urged supplemental guidance related to community benefit and social determinants of health.

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Drug Enforcement Administration (DEA); Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

340B Drug Pricing Program - Highlighted importance of the 340B Drug Pricing program for safety net hospitals and monitored ongoing discussions around reforming the program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Shortages - Advocated for Drug Enforcement Agency to modify total production quotas for injectable opioid solutions to address hospital shortages. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). Opioid Abuse - Supported House passage of H.R. 6 and ongoing efforts to enhance funding and treatment options to address opioid abuse and addiction issues. Overall Hospital Quality Star Ratings - Urged modifications to the methodology used to calculate Overall Hospital Quality Star Ratings Program. Prescription Drug Compounding - Supported ongoing efforts to maintain access to safe and effective drug compounding as the Drug Quality and Safety Act is implemented. Stark Law Reform - Monitored discussions in the House and Senate seeking reforms to the Stark Law. Voiced support for reforms that ease barriers to value-based care arrangements. Medical Device Cybersecurity - Urged additional steps to promote enhanced cybersecurity for networked medical devices.

Contacted: Drug Enforcement Administration (DEA); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2312 (115th), H.R. 4392 (115th), S. 2453 (115th), S. 974 (115th), H.R. 749 (115th), H.R. 6240 (115th), H.R. 6 (115th), S. 297 (115th), S. 124 (115th), H.R. 6071 (115th), H.R. 4710 (115th), H.R. 2051 (115th)

Medicare/Medicaid MMM

340B Drug Pricing Program - Raised opposition to Medicare reimbursement reductions for hospitals eligible for the 340B drug pricing program. Supported passage of H.R. 4392, H.R 6071. Opposed H.R. 4710, H.R. 6240, S. 2312 and S.2453. Supported Limited Repeal of the IMD Exclusion for substance abuse disorder that was included in H.R. 6, the SUPPORT Communities Act. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program.

Contacted: Drug Enforcement Administration (DEA); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 5385 (115th), H.R. 6071 (115th), S. 2453 (115th), H.R. 6240 (115th), H.R. 6 (115th), H.R. 4710 (115th), S. 2312 (115th), S. 2597 (115th), H.R. 4392 (115th)